An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy
Public ClinicalTrials.gov record NCT00938912. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study To Determine Safety, Tolerability And Efficacy Of Long -Term Oral Lacosamide (LCM) As Adjunctive Therapy In Children With Epilepsy
Study identification
- NCT ID
- NCT00938912
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Enrollment
- 366 participants
Conditions and interventions
Conditions
Interventions
- Lacosamide Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Month to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2009
- Primary completion
- May 17, 2021
- Completion
- May 17, 2021
- Last update posted
- Jan 17, 2022
2009 – 2021
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sp848 064 | Birmingham | Alabama | 35233 | — |
| Sp848 059 | Los Angeles | California | 90027-6062 | — |
| Sp848 025 | Sacramento | California | 95815 | — |
| Sp848 002 | Washington D.C. | District of Columbia | 20010 | — |
| Sp848 054 | Orlando | Florida | 32819 | — |
| Sp848 012 | Tampa | Florida | 33609 | — |
| Sp848 019 | Wellington | Florida | 33470 | — |
| Sp848 057 | Augusta | Georgia | 30912-4005 | — |
| Sp848 063 | Saint Paul | Minnesota | 55101 | — |
| Sp848 006 | Saint Paul | Minnesota | 55102 | — |
| Sp848 008 | Kansas City | Missouri | 64108 | — |
| Sp848 061 | Las Vegas | Nevada | 89052 | — |
| Sp848 062 | Hackensack | New Jersey | 07601 | — |
| Sp848 015 | New Brunswick | New Jersey | 08901 | — |
| Sp848 005 | Durham | North Carolina | 27710 | — |
| Sp848 053 | Akron | Ohio | 44308 | — |
| Sp848 068 | Cincinnati | Ohio | 45229 | — |
| Sp848 001 | Philadelphia | Pennsylvania | 19104 | — |
| Sp848 016 | Pittsburgh | Pennsylvania | 15201 | — |
| Sp848 004 | Nashville | Tennessee | 37212 | — |
| Sp848 026 | Austin | Texas | 78723 | — |
| Sp848 067 | Dallas | Texas | 75235 | — |
| Sp848 022 | Houston | Texas | 77076 | — |
| Sp848 020 | Norfolk | Virginia | 23510 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00938912, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2022 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00938912 live on ClinicalTrials.gov.